# Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

> **NCT06734585** · — · COMPLETED · sponsor: **Astellas Pharma Singapore Pte. Ltd.** · enrollment: 114 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gilteritinib

## Key facts

- **NCT ID:** NCT06734585
- **Lead sponsor:** Astellas Pharma Singapore Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-09
- **Primary completion:** 2025-07-14
- **Final completion:** 2025-07-14
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734585, "Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06734585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*